5 SIMPLE STATEMENTS ABOUT AGO TUMOR EXPLAINED

Molecular typing relies on molecular genetic screening and isn't however routinely offered. Molecular subtypes and immunohistochemical surrogate markers with the tumors (HR, HER2, triple adverse) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 can be useful, but a potential